Ceramide-based risk score: A novel laboratory tool for cardiovascular risk stratification in hyperuricemia and gout
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
40239856
DOI
10.1016/j.vph.2025.107495
PII: S1537-1891(25)00034-5
Knihovny.cz E-resources
- Keywords
- Cardiovascular risk, Ceramides, Coronary event risk test, Gout, Hyperuricemia, Lipidomics,
- MeSH
- Biomarkers blood MeSH
- Ceramides * blood MeSH
- Chromatography, Liquid MeSH
- Gout * blood diagnosis complications MeSH
- Adult MeSH
- Risk Assessment MeSH
- Hyperuricemia * blood diagnosis complications MeSH
- Cardiovascular Diseases * diagnosis blood etiology epidemiology MeSH
- Uric Acid * blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Decision Support Techniques * MeSH
- Pilot Projects MeSH
- Predictive Value of Tests MeSH
- Prognosis MeSH
- Heart Disease Risk Factors MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biomarkers MeSH
- Ceramides * MeSH
- Uric Acid * MeSH
Gout and hyperuricemia increase cardiovascular disease risk, highlighting the need for improved risk stratification. In this pilot study, we evaluated the Coronary Event Risk Test (CERT) in 94 hyperuricemic and 196 gout patients, and 53 controls. Plasma ceramides were determined by liquid chromatography-mass spectrometry. Elevated CERT scores (≥7) occurred in 11.7 % (2-fold increase) of hyperuricemic and 31.12 % (5.5-fold increase) of gout patients compared to controls. Additionally, both hyperuricemic and gout patients with increased CERT also exhibited higher levels of inflammation and atherogenic index of plasma, both of which were significantly associated with CERT. Incorporating CERT into routine care may enhance risk stratification and guide targeted interventions in this patient population.
References provided by Crossref.org
